Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia or Bipolar 1 Disorder Under the "New Drug Re-Examination"
Latest Information Update: 16 Feb 2022
Price :
$35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar I disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors Korea Otsuka Pharmaceutical
- 10 Feb 2022 Status changed from recruiting to completed.
- 05 Mar 2019 Planned End Date changed from 1 Dec 2021 to 22 Dec 2021.
- 05 Mar 2019 Planned primary completion date changed from 1 Dec 2021 to 22 Dec 2021.